Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazarotene 0.05% cream for initial and maintenance therapy of lamellar ichthyosis
2010-022284-35Phase 3Completed
- Sponsor
- Orphagen Therapeutics
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tazarotene in lamellar ichthyosis (LI), sponsored by Orphagen Therapeutics. Primary endpoint: Response to test treatment at the end of initial therapy. Started Feb 2011; status: completed.
02
Drugs
tazarotene
03
Conditions
lamellar ichthyosis (LI)
Beyond the preview
Go deeper on 2010-022284-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022284-35.